Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection
Canada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children. The result of the existing programs has been a decrease in serogroup C incide...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2009/871071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565864262533120 |
|---|---|
| author | Nicole Le Saux Julie A Bettinger Susan Wootton Scott A Halperin Wendy Vaudry David W Scheifele Raymond Tsang |
| author_facet | Nicole Le Saux Julie A Bettinger Susan Wootton Scott A Halperin Wendy Vaudry David W Scheifele Raymond Tsang |
| author_sort | Nicole Le Saux |
| collection | DOAJ |
| description | Canada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children. The result of the existing programs has been a decrease in serogroup C incidence. The second most common vaccine-preventable serogroup in Canada is serogroup Y, the incidence of which has been stable. The availability of a quadrivalent conjugate vaccine against serogroups A, C, Y and W135 focuses attention on serogroup Y disease as it becomes relatively more prominent as a cause of vaccine-preventable invasive meningococcal disease. This vaccine was licensed in November 2006 but is not routinely used except in Nunavut, New Brunswick and Prince Edward Island. To allow a better understanding of the ‘value added’ by a serogroup Y-containing vaccine, it is necessary to have a contemporary profile of Y disease in Canada. In the present paper, recent surveillance data on invasive meningococcal disease across Canada are summarized. |
| format | Article |
| id | doaj-art-74e52b0bf9cf4702944a76b120c8a9f5 |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-74e52b0bf9cf4702944a76b120c8a9f52025-02-03T01:06:19ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322009-01-01204e130e13410.1155/2009/871071Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine SelectionNicole Le Saux0Julie A Bettinger1Susan Wootton2Scott A Halperin3Wendy Vaudry4David W Scheifele5Raymond Tsang6Children’s Hospital of Eastern Ontario Research Institute and the University of Ottawa, Ottawa, Ontario, CanadaVaccine Evaluation Center, BC Children’s Hospital and the University of British Columbia, Vancouver, British Columbia, CanadaUniversity of Texas Health Science Center, Houston, Texas, USAClinical Trials Research Center, IWK Health Centre and Dalhousie University, Halifax, Nova Scotia, CanadaStollery Children’s Hospital and University of Alberta, Edmonton, Alberta, CanadaVaccine Evaluation Center, BC Children’s Hospital and the University of British Columbia, Vancouver, British Columbia, CanadaNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, CanadaCanada is a leader in establishing routine infant immunization programs against meningococcal C disease. Currently, all provinces have routine programs to provide meningococcal C conjugate vaccines to infants and children. The result of the existing programs has been a decrease in serogroup C incidence. The second most common vaccine-preventable serogroup in Canada is serogroup Y, the incidence of which has been stable. The availability of a quadrivalent conjugate vaccine against serogroups A, C, Y and W135 focuses attention on serogroup Y disease as it becomes relatively more prominent as a cause of vaccine-preventable invasive meningococcal disease. This vaccine was licensed in November 2006 but is not routinely used except in Nunavut, New Brunswick and Prince Edward Island. To allow a better understanding of the ‘value added’ by a serogroup Y-containing vaccine, it is necessary to have a contemporary profile of Y disease in Canada. In the present paper, recent surveillance data on invasive meningococcal disease across Canada are summarized.http://dx.doi.org/10.1155/2009/871071 |
| spellingShingle | Nicole Le Saux Julie A Bettinger Susan Wootton Scott A Halperin Wendy Vaudry David W Scheifele Raymond Tsang Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection |
| title_full | Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection |
| title_fullStr | Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection |
| title_full_unstemmed | Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection |
| title_short | Profile of Serogroup Y Meningococcal Infections in Canada: Implications for Vaccine Selection |
| title_sort | profile of serogroup y meningococcal infections in canada implications for vaccine selection |
| url | http://dx.doi.org/10.1155/2009/871071 |
| work_keys_str_mv | AT nicolelesaux profileofserogroupymeningococcalinfectionsincanadaimplicationsforvaccineselection AT julieabettinger profileofserogroupymeningococcalinfectionsincanadaimplicationsforvaccineselection AT susanwootton profileofserogroupymeningococcalinfectionsincanadaimplicationsforvaccineselection AT scottahalperin profileofserogroupymeningococcalinfectionsincanadaimplicationsforvaccineselection AT wendyvaudry profileofserogroupymeningococcalinfectionsincanadaimplicationsforvaccineselection AT davidwscheifele profileofserogroupymeningococcalinfectionsincanadaimplicationsforvaccineselection AT raymondtsang profileofserogroupymeningococcalinfectionsincanadaimplicationsforvaccineselection |